CytomX Therapeutics - CTMX Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares.
View CTMX analyst ratings or view top-rated stocks.

11 analysts have issued 1 year price targets for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $3.46 in the next twelve months. This suggests a possible upside of 94.8% from the stock's current price.
View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts.

CytomX Therapeutics' stock was trading at $1.60 on January 1st, 2023. Since then, CTMX stock has increased by 10.9% and is now trading at $1.7750.
View the best growth stocks for 2023 here.

CytomX Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,880,000 shares, an increase of 48.0% from the February 28th total of 1,270,000 shares. Based on an average daily trading volume, of 2,490,000 shares, the short-interest ratio is currently 0.8 days. Approximately 2.9% of the shares of the stock are short sold.
View CytomX Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our CTMX earnings forecast.

CytomX Therapeutics will be holding an earnings conference call on Monday, March 27th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.05. The biotechnology company had revenue of $17.59 million for the quarter, compared to analyst estimates of $18.53 million. CytomX Therapeutics had a negative trailing twelve-month return on equity of 166.29% and a negative net margin of 135.65%. During the same period in the previous year, the company earned ($0.32) earnings per share.

ETFs with the largest weight of CytomX Therapeutics (NASDAQ:CTMX) stock in their portfolio include Formidable ETF (FORH).Invesco Nasdaq Future Gen 200 ETF (QQQS).

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

CytomX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (5.31%), Millennium Management LLC (2.60%), Renaissance Technologies LLC (2.03%), Assenagon Asset Management S.A. (1.38%), Two Sigma Investments LP (1.12%) and Platinum Investment Management Ltd. (0.96%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends.

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CTMX stock can currently be purchased for approximately $1.78.

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $117.29 million and generates $69.57 million in revenue each year. The biotechnology company earns $-83,610,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

The company employs 174 workers across the globe.

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.